Heat shock protein 90 (Hsp90) consists of four isoforms. Among them, the Hsp90α is overexpressed in advanced tumors and involved in tissue repair, tumor migration and metastasis as well. Researchers from Fujian Medical University (FJMU) reported on the discovery and preclinical characterization of [I], a selective proteolysis targeting chimera (PROTAC) acting as an Hsp90α protein degradation inducer for breast cancer treatment.
GSK plc is the latest pharma giant to bite the “magic bullet” of antibody-drug conjugate (ADC) drugs, promising to pay the Chinese immunotherapy developer Hansoh Pharmaceutical Co. Ltd. $85 million up front and over $1.4 billion in milestone payments in a licensing deal for HS-20089.
Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?
GSK plc is the latest pharma giant to bite the “magic bullet” of antibody-drug conjugate (ADC) drugs, promising to pay the Chinese immunotherapy developer Hansoh Pharmaceutical Co. Ltd. $85 million up front and over $1.4 billion in milestone payments in a licensing deal for HS-20089.
Ideaya Biosciences Inc. has described piperazine substituted indazole compounds acting as poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Autotelic Bio Inc. has divulged thiazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer.
Duality Biologics (Suzhou) Co. Ltd. has synthesized antibody-drug conjugates comprising anti-GPC3 antibodies covalently linked to exatecan derivatives through a linker. They are reported to be useful for the treatment of cancer.
Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.
